Related Experiment Video
Updated: May 5, 2026
08:42
A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics
Published on: September 19, 2016
8.3K
Protease-activated receptors in cardiovascular diseases
Andrew J Leger1, Lidija Covic, Athan Kuliopulos
1Hemostasis and Thrombosis Laboratory, Division of Hematology/Oncology, Molecular Oncology Research Institute, Tufts-New England Medical Center, Boston, MA 02111, USA.
Circulation
|September 6, 2006
Summary
Small molecule inhibitors targeting protease-activated receptor-1 (PAR1) show promise for treating thrombosis. New pepducin inhibitors reveal previously unknown roles for PAR1 and PAR4 in protease signaling.
Area of Science:
- Cardiovascular Medicine
- Molecular Pharmacology
- Protease Signaling
Background:
- Thrombosis involves platelet and vascular cell activation, highlighting the importance of thrombin and its receptors.
- Thrombin signaling via protease-activated receptors (PARs) affects platelet activation, inflammation, and vascular function.
- PAR1 and PAR4 are validated targets for preventing thrombosis and restenosis in animal models.
Purpose of the Study:
- To describe the molecular and pharmacological basis of small-molecule inhibitors targeting PAR1.
- To explore the role of PAR1 and PAR4 in protease signaling using novel cell-penetrating inhibitors (pepducins).
Main Methods:
- Development and characterization of small-molecule PAR1 inhibitors.
- Utilizing pepducins to investigate PAR1 and PAR4 function in protease signaling.
Main Results:
- Established the molecular and pharmacological profile of PAR1-targeting small molecules.
- Identified novel roles for PAR1 and PAR4 in protease signaling through pepducin studies.
Conclusions:
- Small-molecule inhibitors targeting PAR1 offer a therapeutic strategy for thrombosis.
- Pepducins provide new insights into the complex roles of PAR1 and PAR4 in cellular signaling.
Related Concept Videos
01:00Enzyme-linked Receptors
64.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
64.6K
01:21G-Protein Gated Ion Channels
5.5K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
5.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
01:31Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
765
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765